Evidence map›Paper›PMID 38185757›Full record

ArticleCell proliferation2024

Cardiopulmonary progenitors facilitate cardiac repair via exosomal transfer of miR-27b-3p targeting the SIK1-CREB1 axis.

Ying-Ying Xiao, Luo-Xing Xia, Wen-Jing Jiang, Jian-Feng Qin, Li-Xin Zhao, Zhan Li, Li-Juan Huang, Ke-Xin Li, Peng-Jiu Yu, Li Wei and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell proliferation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Integrative single-cell analysis revealsFrontiers in immunology · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Ying-Ying XiaoKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Luo-Xing XiaKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Wen-Jing JiangKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Jian-Feng QinKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Li-Xin ZhaoKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Zhan LiKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Li-Juan HuangKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Ke-Xin LiKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Peng-Jiu YuDepartment of Pharmacy, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Li WeiDepartment of Pharmacy, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Xue-Yan JiangKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Institute for Biotechnology, St. John's University, Queens, New York, USA.ORCID https://orcid.org/0000-0002-8289-097X
Xi-Yong YuKey Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital & the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID https://orcid.org/0000-0003-4988-7338
State Key Laboratory of Respiratory Disease · CNFirst Affiliated Hospital of Guangzhou Medical University · CNSt. John's University · US

Funding

China Postdoctoral Science Foundation 2022M710890Guangdong Provincial Drug Administration Science and Technology Innovation Project - Key Technology Research on Chest Disease Prevention and Treatment Drug Research and Clinical Evaluation 2022ZDZ10Guangzhou Medical University 06-410-2107211National Key Research and Development Program of China 2022YFE0209700National Natural Science Foundation of China 81900284Natural Science Foundation of Guangdong Province 2019A1515011300
6 · The paper itself

Abstract

Ischemic heart disease, especially myocardial infarction (MI), is one of the leading causes of death worldwide, and desperately needs effective treatments, such as cell therapy. Cardiopulmonary progenitors (CPPs) are stem cells for both heart and lung, but their repairing role in damaged heart is still unknown. Here, we obtained CPPs from E9.5 mouse embryos, maintained their stemness while expanding, and identified their characteristics by scRNA-seq, flow cytometry, quantitative reverse transcription-polymerase chain reaction, and differentiation assays. Moreover, we employed mouse MI model to investigate whether CPPs could repair the injured heart. Our data identified that CPPs exhibit hybrid fibroblastic, endothelial, and mesenchymal state, and they could differentiate into cell lineages within the cardiopulmonary system. Moreover, intramyocardial injection of CPPs improves cardiac function through CPPs exosomes (CPPs-Exo) by promotion of cardiomyocytic proliferation and vascularization. To uncover the underlying mechanism, we used miRNA-seq, bulk RNA-seq, and bioinformatic approaches, and found the highly expressed miR-27b-3p in CPPs-Exo and its target gene Sik1, which can influence the transcriptional activity of CREB1. Therefore, we postulate that CPPs facilitate cardiac repair partially through the SIK1-CREB1 axis via exosomal miR-27b-3p. Our study offers a novel insight into the role of CPPs-Exo in heart repair and highlights the potential of CPPs-Exo as a promising therapeutic strategy for MI.

Indexed as

Cyclic AMP Response Element-Binding ProteinExosomesMicroRNAsAnimalsCell DifferentiationCell ProliferationLungMiceMice, Inbred C57BLMyocardial InfarctionMyocardiumProtein Serine-Threonine KinasesStem CellsCreb1 protein, mouseCyclic AMP Response Element-Binding ProteinMicroRNAsMirn27 microRNA, mouseProtein Serine-Threonine Kinases

Identifiers

PMID38185757
PMCPMC11056695
OpenAlexW4390655008

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.